Research Paper Volume 13, Issue 1 pp 1186—1211
MicroRNA-139-5p upregulation is associated with diabetic endothelial cell dysfunction by targeting c-jun
Figure 7. MiR-139-5p inhibits VEGF expression by c-jun to inhibit the function of ECFCs. (A) PDGF-B and VEGF expression detected by Western blot in healthy and diabetic subjects. (N=3) *P < .05 versus normal ECFCs. (B) C-jun, VEGF, and PDGF-B expression in normal ECFCs transfected with miR-139-5p mimics and diabetic ECFCs transfected with a miR-139-5p inhibitors. (N=3) *P < .05 versus normal or diabetic ECFCs. (C) C-jun, VEGF, and PDGF-B expression was detected when normal ECFCs were transfected with miR-139-5p mimics and c-jun plasmids and diabetic ECFCs were transfected with miR-139-5p inhibitors and c-jun siRNA. (N=3) *P < .05 versus normal or diabetic ECFCs. (D) C-jun and VEGF expression was detected in normal ECFCs co-transfected with miR-139-5p mimics and c-jun plasmid, whereas diabetic ECFCs were co-transfected with miR-139-5p inhibitors and c-jun siRNA. The immunofluorescence was used to identify the c-jun and VEGF expression. Red indicates Cy3-labeled c-jun and green indicate FITC-labeled VEGF. The photos were captured by a 40X fluorescence microscope. (N=3) *P < .05. Data shown in the graphs represent mean ± standard deviation.